Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2024-03-15 Eckburg Paul Chief Medical Officer Grant or award +30,000 51,416
2024-03-15 Day Lucy Chief Financial Officer Grant or award +27,500 30,627
2024-03-15 Eizen Joshua M Chief Legal Officer Grant or award +30,000 32,447
2024-03-15 Krause Kevin Michael Chief Strategy Officer Grant or award +30,000 31,914
2024-03-15 Chanda Sanjay Chief Development Officer Grant or award +27,500 28,235
2024-03-15 Easom Eric Chief Executive Officer Grant or award +99,000 101,130
2024-03-15 Day Lucy Chief Financial Officer Grant or award +27,500 30,627
2024-03-15 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) +55,000 55,000
2024-03-15 Eizen Joshua M Chief Legal Officer Grant or award +30,000 32,447
2024-03-15 Eizen Joshua M Chief Legal Officer Grant or award · Stock Option (right to buy) +60,000 60,000
2024-03-15 Krause Kevin Michael Chief Strategy Officer Grant or award +30,000 31,914
2024-03-15 Krause Kevin Michael Chief Strategy Officer Grant or award · Stock Option (right to buy) +60,000 60,000
2024-03-15 Chanda Sanjay Chief Development Officer Grant or award +27,500 28,235
2024-03-15 Chanda Sanjay Chief Development Officer Grant or award · Stock Option (right to buy) +55,000 55,000
2024-03-15 Eckburg Paul Chief Medical Officer Grant or award +30,000 51,416
2024-03-15 Eckburg Paul Chief Medical Officer Grant or award · Stock Option (right to buy) +60,000 60,000
2024-03-15 Easom Eric Chief Executive Officer Grant or award +99,000 101,130
2024-03-15 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +198,000 198,000
2024-01-18 Zakrzewski Joseph S Director Sale −100,000 $19.11 $1.9M 405,880
2024-01-16 Aziz Kabeer Director Sale −84,093 $19.65 $1.7M 1,995,958

Page 11 of 20 · 385 trades